Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Séverine Cruet-Hennequart"'
Autor:
Séverine Cruet-Hennequart, Carole Drougard, Georgina Shaw, Florence Legendre, Magali Demoor, Frank Barry, Jean-Louis Lefaix, Philippe Galéra
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119334 (2015)
While human mesenchymal stem cells (hMSCs), either in the bone marrow or in tumour microenvironment could be targeted by radiotherapy, their response is poorly understood. The oxic effects on radiosensitivity, cell cycle progression are largely unkno
Externí odkaz:
https://doaj.org/article/ec50001db6a14aa78b5f89a2d7d9ce41
Autor:
Denis Agostini, Damien Peyronnet, Gilbert Pigrée, Séverine Cruet-Hennequart, Christian Marcelli, Pierre Barbey, Jonathan Vigne, Johann Cesini
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (8), pp.1591-1593. ⟨10.1007/s00259-019-04335-2⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (8), pp.1591-1593. ⟨10.1007/s00259-019-04335-2⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77dbb079aee1f28e06d5a18372d4c6dc
https://hal-normandie-univ.archives-ouvertes.fr/hal-02190536
https://hal-normandie-univ.archives-ouvertes.fr/hal-02190536
Publikováno v:
International Journal of Hematology. 96:649-656
Anthracyclines, including doxorubicin, are widely used in the treatment of leukemia. While the effects of doxorubicin on hematopoietic cells have been characterized, less is known about the response of human mesenchymal stem cells (hMSCs) in the bone
Publikováno v:
Cell Cycle. 10:3768-3777
DNA damaging agents are widely used in treatment of hematogical malignancies and solid tumors. While effects on hematopoietic stem cells have been characterized, less is known about the DNA damage response in human mesenchymal stem cells (hMSCs) in t
Autor:
Anna M. Sokol, Elaine O'Meara, Sangamitra Villalan, Séverine Cruet-Hennequart, Michael P. Carty, Agnieszka Kaczmarczyk
Publikováno v:
Cell Cycle. 8:3043-3054
Translesion synthesis by DNA polymerase eta (poleta) is one mechanism by which cancer cells can tolerate DNA damage by platinum-based anti-cancer drugs. Cells lacking poleta are sensitive to these agents. To help define the consequences of poeta-defi
Publikováno v:
DNA Repair. 7:582-596
The chemotherapeutic drugs cisplatin and oxaliplatin act by induction of DNA damage, including monoadducts, intrastrand and interstrand crosslinks. An increased understanding of the repair and replication of platinum-damaged DNA is required to improv
Autor:
Eva Szegezdi, Michael P. Carty, Séverine Cruet-Hennequart, Tanja Paavilainen, Afshin Samali, Michael O'Dwyer, Réka Tóth
Publikováno v:
Journal of Leukemia.
Erythroidl eukemia is a heterogeneous disease with very poor prognosis. It may arise de novo, secondary to myelodysplastic syndrome, blast crisis phase of chronic myeloid leukemia, or after cytotoxic therapy of acute myeloid leukemia. The current mai
Autor:
Yves Denoux, Sylvie Maubant, Hubert Crouet, Pascal Gauduchon, Séverine Cruet-Hennequart, Michel Henry-Amar, Soizic Dutoit
Publikováno v:
Journal of Molecular Histology. 36:119-129
The aim of the study was to investigate the relationships between the expression of alphav, beta1, beta3, beta5, and beta6, integrin subunits and clinical parameters in ovarian cancers. Ovarian surface epithelium (OSE) from five donors and tumour sam
Autor:
Jeff Wheeler, Jasbinder S. Sanghera, Penny Costello, Martin E. Gleave, Shoukat Dedhar, Clara Tan, Armelle Troussard, Kym Sutton, Séverine Cruet-Hennequart, Ladan Fazli
Publikováno v:
Cancer Cell. 5:79-90
We show that integrin-linked kinase (ILK) stimulates the expression of VEGF by stimulating HIF-1alpha protein expression in a PKB/Akt- and mTOR/FRAP-dependent manner. In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibiti
Publikováno v:
Cancer genomicsproteomics. 7(5)
Cancer chemotherapy relies heavily on DNA damaging agents such as cisplatin to induce tumour cell death. The response of cells to genotoxic insult, including cell cycle arrest, DNA repair and cell death, is mediated by the DNA damage response (DDR).